ReviewFrontiers in immunology2026
Molecular mimicry revisited: novel perspectives on autoimmune disease initiation and progression.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular mimicry has long been implicated as one possible mechanism linking pathogen infection to autoimmunity, yet firm proof of its contribution to disease initiation and/or progression remains incompletely defined. In this review, we revisit the concept of molecular mimicry in light of recent advances in immunology, structural biology, and systems medicine. Beyond classical sequence homology, emerging evidence highlights the importance of structural and conformational epitope similarity, post-translational modifications, and context-dependent antigen presentation in shaping cross-reactive immune responses. We discuss how these factors influence the activation of autoreactive T and B cells, the breakdown of immune tolerance, and the establishment of chronic autoimmune disease. We further reevaluate the body of evidence for molecular mimicry as inducer and/or accelerator of specific autoimmune diseases ranging from mere association to proven causative relationship. Thereby, we further examine novel experimental approaches that have refined the identification of mimicry candidates and improved our understanding of their pathogenic relevance. By integrating classical paradigms with contemporary findings, this review provides a detailed outline for understanding molecular mimicry as a dynamic and multi-layered contributor to autoimmune disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.